NHS Cost-Effectiveness Thresholds Boost Drug Ap...

By João L. Carapinha

January 12, 2026

Confirmation of Adjusted Cost-Effectiveness Thresholds for NHS Medicines Evaluations The UK's National Institute for Health and Care Excellence (
Driving Economic Transformation through Brain Health Investment in Africa
Novartis Drug Pricing Agreement
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
Preparing for the EU Health Technology Assessment: Key Insights from the Upco...
Transforming EU Pharmaceutical Legislation: EMA’s Strategic Priorities ...
Strategic Avalere Health Appointments Enhance Leadership in Navigating US Hea...
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggress...
Translational Medicine Portugal: Driving Collaborative Innovations in Healthcare
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solut...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Strengthening EU Pharmaceutical Supply Security Through the Critical Medicine...